Andrew Weisenfeld

Mr. Weisenfeld has been an investment banker since 1989. Mr. Weisenfeld became a Partner at MTS Health Partners in January 2008, primarily responsible for the development of the life sciences and medical technology practices. Prior to joining, Mr. Weisenfeld was a Managing Director in Banc of America Securities’ Corporate and Investment Banking Healthcare Group. Mr. Weisenfeld co-led the firm’s life sciences practice, providing capital raising and strategic advisory services to both publicly traded and private companies. Prior to joining Bank of America in 2003, Mr. Weisenfeld was a Managing Director at JP Morgan and its predecessor company, Chase Securities, leading its Healthcare M&A business across all sectors of healthcare from middle of 1997 to beginning of 2003. Prior to joining Chase, Mr. Weisenfeld spent over five years in the M&A Group at Merrill Lynch. Throughout his career, Mr. Weisenfeld has worked on a wide range of advisory transactions including acquisitions, sale transactions and strategic relationships. Selected life sciences transactions include the sale of Veloxis to Asahi, the acquisition of Alder by Lundbeck, the merger of Keryx with Akebia, the sale of Colucid to Lilly, the sale of Celator to Jazz Pharmaceuticals, Otsuka’s acquisitions of Avanir and Neurovance, reverse merger transactions for Neoleukin, Synta (to become Madrigal), Regado (to become Tobira) and Trimeris (to become Synageva), Reata’s strategic partnership with Abbott Labs, Genzyme’s acquisition of Bioenvision, the sale of Corixa to GlaxoSmithKline, the sale of TKT to Shire, and the sale of ALZA to J&J. Mr. Weisenfeld has also been responsible for many life sciences financings, including such as the monetization of Immunogen’s Kadcyla’s royalty and acting as advisor in the Alder, Tracon and NuPathe IPOs. Mr. Weisenfeld is a board member of Public Health Solutions, a New York based not-for-profit. Mr. Weisenfeld is also an active alumnus of Cornell University, acting as a member of the scientific advisory committee of Weill Cornell Medical School’s Daedalus Fund for Innovation and the school’s Dean’s Council as well as a member of the Cornell Dyson School’s Undergraduate Program Advisory Council. Mr. Weisenfeld holds an MBA from The Wharton School at the University of Pennsylvania and a BS from Cornell University.